Vor Biopharma reported second quarter financial results in August and provided a business update which included an announcement that the company has begun construction on manufacturing facility to be added to its headquarters in Cambridge. The new manufacturing facility is designed to support clinical manufacturing for Vor’s cell therapy programs, including both eHSCs and CAR-T […]

Pfizer will acquire Cambridge-based Trillium, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium for $2.26 billion, or $18.50 per share.  This represents a 118% premium to the 60-day weighted average price for Trillium. Trillium’s portfolio includes […]

The Massachusetts Biotechnology Council has released its 2021 Industry Snapshot, which shows incredible growth across the life sciences industry and also reveals forthcoming opportunities and challenges. The report found that Massachusetts-headquartered biopharma companies raised $4.3 billion in venture capital (VC) funding in the first quarter of 2021, already nearing the industry’s peak of $5.8 billion in […]

Cambridge-based startup Nuvalent has closed its upsized initial public offering of 11,212,500 shares of common stock, at a price to the public of $17.00 per share. The gross proceeds of the offering were approximately $190.6 million, before deducting underwriting discounts and commissions and other offering expenses. Nuvalent, which launched in January 2021, is creating precisely […]

Medford-based synthetic biology company GreenLight Biosciences has agreed to merge with Environmental Impact Acquisition Corp., a publicly traded special purpose acquisition company or SPAC, in a transaction that will result in GreenLight becoming a publicly-listed company. After the close of the transaction, expected in Q4 of 2021, the combined company will be listed on Nasdaq […]